173 related articles for article (PubMed ID: 9236673)
1. Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-alpha (cA2) therapy.
Brennan FM; Browne KA; Green PA; Jaspar JM; Maini RN; Feldmann M
Br J Rheumatol; 1997 Jun; 36(6):643-50. PubMed ID: 9236673
[TBL] [Abstract][Full Text] [Related]
2. Anti-tumour necrosis factor (TNF)-alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis.
Catrina AI; Lampa J; Ernestam S; af Klint E; Bratt J; Klareskog L; Ulfgren AK
Rheumatology (Oxford); 2002 May; 41(5):484-9. PubMed ID: 12011369
[TBL] [Abstract][Full Text] [Related]
3. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers.
Keyszer G; Lambiri I; Nagel R; Keysser C; Keysser M; Gromnica-Ihle E; Franz J; Burmester GR; Jung K
J Rheumatol; 1999 Feb; 26(2):251-8. PubMed ID: 9972954
[TBL] [Abstract][Full Text] [Related]
4. Levels of circulating collagenase, stromelysin-1, and tissue inhibitor of matrix metalloproteinases 1 in patients with rheumatoid arthritis. Relationship to serum levels of antigenic keratan sulfate and systemic parameters of inflammation.
Manicourt DH; Fujimoto N; Obata K; Thonar EJ
Arthritis Rheum; 1995 Aug; 38(8):1031-9. PubMed ID: 7639798
[TBL] [Abstract][Full Text] [Related]
5. Effect of repeated infliximab therapy on serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis.
Klimiuk PA; Sierakowski S; Domyslawska I; Chwiecko J
J Rheumatol; 2004 Feb; 31(2):238-42. PubMed ID: 14760791
[TBL] [Abstract][Full Text] [Related]
6. Early joint erosions and serum levels of matrix metalloproteinase 1, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinases 1 in rheumatoid arthritis.
Cunnane G; Fitzgerald O; Beeton C; Cawston TE; Bresnihan B
Arthritis Rheum; 2001 Oct; 44(10):2263-74. PubMed ID: 11665967
[TBL] [Abstract][Full Text] [Related]
7. Matrix metalloproteinases MMP-3 and MMP-1 levels in sera and synovial fluids in patients with rheumatoid arthritis and osteoarthritis.
Mahmoud RK; El-Ansary AK; El-Eishi HH; Kamal HM; El-Saeed NH
Ital J Biochem; 2005; 54(3-4):248-57. PubMed ID: 16688934
[TBL] [Abstract][Full Text] [Related]
8. Expression of matrix metalloproteinase 9 (96-kd gelatinase B) in human rheumatoid arthritis.
Ahrens D; Koch AE; Pope RM; Stein-Picarella M; Niedbala MJ
Arthritis Rheum; 1996 Sep; 39(9):1576-87. PubMed ID: 8814070
[TBL] [Abstract][Full Text] [Related]
9. Active synovial matrix metalloproteinase-2 is associated with radiographic erosions in patients with early synovitis.
Goldbach-Mansky R; Lee JM; Hoxworth JM; Smith D; Duray P; Schumacher RH; Yarboro CH; Klippel J; Kleiner D; El-Gabalawy HS
Arthritis Res; 2000; 2(2):145-53. PubMed ID: 11062605
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the cell infiltrate and expression of proinflammatory cytokines and matrix metalloproteinases in arthroscopic synovial biopsies: comparison with synovial samples from patients with end stage, destructive rheumatoid arthritis.
Smeets TJ; Barg EC; Kraan MC; Smith MD; Breedveld FC; Tak PP
Ann Rheum Dis; 2003 Jul; 62(7):635-8. PubMed ID: 12810425
[TBL] [Abstract][Full Text] [Related]
11. Pannus invasion and cartilage degradation in rheumatoid arthritis: involvement of MMP-3 and interleukin-1beta.
Ainola MM; Mandelin JA; Liljeström MP; Li TF; Hukkanen MV; Konttinen YT
Clin Exp Rheumatol; 2005; 23(5):644-50. PubMed ID: 16173240
[TBL] [Abstract][Full Text] [Related]
12. Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondylarthropathy.
Vandooren B; Kruithof E; Yu DT; Rihl M; Gu J; De Rycke L; Van Den Bosch F; Veys EM; De Keyser F; Baeten D
Arthritis Rheum; 2004 Sep; 50(9):2942-53. PubMed ID: 15457463
[TBL] [Abstract][Full Text] [Related]
13. Matrix metalloproteinases, but not cathepsins B, H, and L or their inhibitors in peripheral blood of patients with rheumatoid arthritis are potentially useful markers of disease activity.
Keyszer G; Lambiri I; Keysser M; Keysser C; Nagel R; Burmester GR; Jung K
Z Rheumatol; 1998 Dec; 57(6):392-8. PubMed ID: 10025098
[TBL] [Abstract][Full Text] [Related]
14. Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C. Relationship to interferon response.
Kasahara A; Hayashi N; Mochizuki K; Oshita M; Katayama K; Kato M; Masuzawa M; Yoshihara H; Naito M; Miyamoto T; Inoue A; Asai A; Hijioka T; Fusamoto H; Kamada T
J Hepatol; 1997 Mar; 26(3):574-83. PubMed ID: 9075665
[TBL] [Abstract][Full Text] [Related]
15. Connective tissue metabolism in patients with unclassified polyarthritis and early rheumatoid arthritis. Relationship to disease activity, bone mineral density, and radiographic outcome.
Jensen T; Klarlund M; Hansen M; Jensen KE; Skjødt H; Hyldstrup L;
J Rheumatol; 2004 Sep; 31(9):1698-708. PubMed ID: 15338487
[TBL] [Abstract][Full Text] [Related]
16. The active form of MMP-3 is a marker of synovial inflammation and cartilage turnover in inflammatory joint diseases.
Sun S; Bay-Jensen AC; Karsdal MA; Siebuhr AS; Zheng Q; Maksymowych WP; Christiansen TG; Henriksen K
BMC Musculoskelet Disord; 2014 Mar; 15():93. PubMed ID: 24641725
[TBL] [Abstract][Full Text] [Related]
17. Determination of stromelysin-1, 72 and 92 kDa type IV collagenase, tissue inhibitor of metalloproteinase-1 (TIMP-1), and TIMP-2 in synovial fluid and serum from patients with rheumatoid arthritis.
Ishiguro N; Ito T; Obata K; Fujimoto N; Iwata H
J Rheumatol; 1996 Sep; 23(9):1599-604. PubMed ID: 8877931
[TBL] [Abstract][Full Text] [Related]
18. Reduced chemokine and matrix metalloproteinase expression in patients with rheumatoid arthritis achieving remission.
Katrib A; Smith MD; Ahern MJ; Slavotinek J; Stafford L; Cuello C; Bertouch JV; McNeil HP; Youssef PP
J Rheumatol; 2003 Jan; 30(1):10-21. PubMed ID: 12508384
[TBL] [Abstract][Full Text] [Related]
19. Preferential induction of prodestructive matrix metalloproteinase-1 and proinflammatory interleukin 6 and prostaglandin E2 in rheumatoid arthritis synovial fibroblasts via tumor necrosis factor receptor-55.
Alsalameh S; Amin RJ; Kunisch E; Jasin HE; Kinne RW
J Rheumatol; 2003 Aug; 30(8):1680-90. PubMed ID: 12913922
[TBL] [Abstract][Full Text] [Related]
20. Acute-phase serum amyloid A regulates tumor necrosis factor α and matrix turnover and predicts disease progression in patients with inflammatory arthritis before and after biologic therapy.
Connolly M; Mullan RH; McCormick J; Matthews C; Sullivan O; Kennedy A; FitzGerald O; Poole AR; Bresnihan B; Veale DJ; Fearon U
Arthritis Rheum; 2012 Apr; 64(4):1035-45. PubMed ID: 22076945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
